Spark Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced total revenue was USD 13.503 million compared to USD 25.185 million a year ago. Operating loss was USD 66.445 million compared to USD 34.599 million a year ago. Net loss was USD 64.230 million compared to net income of USD 80.165 million a year ago. Basic loss per share was USD 1.66 compared to basic earnings per share of USD 2.15 a year ago. Diluted loss per share was USD 1.66 compared to diluted earnings per share of USD 2.07 a year ago. For the half year, total revenue was USD 34.274 million compared to USD 40.861 million a year ago. Operating loss was USD 123.291 million compared to USD 83.511 million a year ago. Net loss was USD 118.588 million compared to net income of USD 33.792 million a year ago. Basic loss per share was USD 3.1 compared to basic earnings per share of USD 0.91 a year ago. Diluted loss per share was USD 3.1 compared to diluted earnings per share of USD 0.88 a year ago.